{"filing":{"accession_number":"0001819790-26-000043","cik":"0001819790","ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tars-20260625.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000043/tars-20260625.htm"},"events":[{"id":14652,"run_id":13054,"accession_number":"0001819790-26-000043","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Tarsus Pharmaceuticals' Annual Meeting of Stockholders held on June 25, 2026. The filing reports voting outcomes on three proposals: election of four Class III directors, advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a routine but material governance disclosure required under Item 5.07 of Form 8-K.","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12144,"accession_number":"0001819790-26-000043","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Tarsus Pharmaceuticals' Annual Meeting of Stockholders held on June 25, 2026. The filing reports voting outcomes on three proposals: election of four Class III directors, advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a routine but material governance disclosure required under Item 5.07 of Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:20:39.167035+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12144,"accession_number":"0001819790-26-000043","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Tarsus Pharmaceuticals' Annual Meeting of Stockholders held on June 25, 2026. The filing reports voting outcomes on three proposals: election of four Class III directors, advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a routine but material governance disclosure required under Item 5.07 of Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:20:39.167035+00:00","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-06-29"}]}